← Back to Clinical Trials
Recruiting Phase 4 NCT04347473

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Trial Parameters

Condition Psoriasis
Sponsor Psoriasis Treatment Center of Central New Jersey
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 25
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2020-04-06
Completion 2020-12-30
Interventions
Ilumya Injectable Product

Brief Summary

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Eligibility Criteria

Inclusion Criteria: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by * BSA 10% * PGA ≥3 * PASI ≥12 3. Must be a candidate for phototherapy and/or systemic therapy 4. Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide. Exclusion Criteria: 1. Non-plaque forms of psoriasis 2. Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating 3. Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial. 4

Related Trials